Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation For Cysteamine In Huntington's Disease (Medical News Today)
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), announced that the U.S. Food and Drug Administration ("FDA") has granted orphan drug designation for cysteamine bitartrate ("cysteamine") for the treatment of Huntington's disease ("HD").

Brain drain dogs FDA (The Washington Times)
When pharmaceutical consulting firm Quintiles wants to hire a new employee, the first place it looks is the Food and Drug Administration.